Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
A new hypothesis is presented on the function of factor XII, which is postulated to be a "missing link" between acute stress and transient hypercoagulability. The implications of this idea are developed to show how chronic stress, which involves activation of hypertension and migraine as well as hypercoagulability, can cause of cerebrovascular disease. "Acute stress" is defined as "the normal short-term physiological response to the perception of major threats or demands". "Chronic stress" is "the abnormal ongoing physiological response to the continuing perception of unresolvable major threats or demands". The factor XII hypothesis is as follows: Acute stress includes release of epinephrine by the adrenal medulla. Epinephrine activates platelets by binding to alpha-2A adrenergic receptors. Activated platelets convert pre-bound factor XII to its active form, which then initiates the intrinsic coagulation cascade. This can be called the "activated platelet initiation pathway" for coagulation. Neither tissue factor nor pre-formed thrombin is required. Thrombosis proceeds to completion, but only a minute amount of thrombin is formed, and the process normally stops at this point. In people who lapse into a state of chronic stress, essential hypertension, which is also a manifestation of stress, synergizes with hypercoagulability: there is both a baseline rise in blood pressure and systemic platelet activation as well as superimposed labile rises of both. Upregulation of these two stress parameters is atherogenic: epinephrine-activated platelets stimulating thrombin formation interact with endothelial cells activated by angiotensin II to cause, first, smooth muscle cell proliferation, which is a histological hallmark of atherosclerosis, and, lastly, a symptomatic thrombotic occlusion-the stroke. The migraine symptoms which often accompany this process are a marker of chronic stress and ongoing pathophysiologic damage. Therapeutic predictions are made regarding novel ways of blocking stress-induced hypercoagulability and hypertension. Hypercoagulability could be targeted by monoclonal antibodies directed against the platelet-specific alpha-2 adrenergic receptor or the (putative) platelet receptor for Factor XII; hypertension could be treated with monoclonal antibodies directed against the beta-adrenergic receptor in the juxtaglomerular apparatus or by surgical denervation of the kidneys, either of which would decrease the renin release which helps drive the hypertension.
Eggers
Arnold E
AE
Department of Neurology, SUNY-Downstate Medical Center, 450 Clarkson Ave., Box 1213, Brooklyn, NY 11203, USA.
D000679:Amygdala / Q000503:physiopathology; D050197:Atherosclerosis / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D001342:Autonomic Nervous System Diseases / Q000453:epidemiology / Q000503:physiopathology; D001777:Blood Coagulation / Q000502:physiology*; D001778:Blood Coagulation Disorders / Q000453:epidemiology*; D004837:Epinephrine / Q000097:blood; D005174:Factor XII / Q000096:biosynthesis / Q000378:metabolism*; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D002546:Ischemic Attack, Transient / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D012084:Renin-Angiotensin System / Q000502:physiology; D020521:Stroke / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy
D005174:Factor XII; D004837:Epinephrine